"Hallucinogens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise.
| Descriptor ID |
D006213
|
| MeSH Number(s) |
D27.505.696.388 D27.505.954.427.700.372
|
| Concept/Terms |
Hallucinogens- Hallucinogens
- Psychotomimetic Agents
- Agents, Psychotomimetic
- Hallucinogenic Agents
- Agents, Hallucinogenic
- Hallucinogenic Substances
- Substances, Hallucinogenic
- Psychedelics
- Psychedelic Agents
- Agents, Psychedelic
- Hallucinogenic Drugs
- Drugs, Hallucinogenic
|
Below are MeSH descriptors whose meaning is more general than "Hallucinogens".
Below are MeSH descriptors whose meaning is more specific than "Hallucinogens".
This graph shows the total number of publications written about "Hallucinogens" by people in this website by year, and whether "Hallucinogens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2009 | 1 | 2 | 3 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 0 | 3 |
| 2022 | 5 | 1 | 6 |
| 2023 | 4 | 0 | 4 |
| 2024 | 5 | 1 | 6 |
| 2025 | 4 | 0 | 4 |
| 2026 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hallucinogens" by people in Profiles.
-
Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology. Expert Opin Drug Discov. 2026 Aug; 21(8):855-864.
-
Mescaline Alters Cerebellar Function, Global Connectivity, and Frequency-Selective Acoustic Gating: A BOLD fMRI Study in Awake Rats. Neurosci Bull. 2026 Oct; 42(10):2219-2237.
-
Capacity Building Through Psychedelic-Assisted Therapy: Navigating Social Determinants of Health. Psychiatr Clin North Am. 2026 Sep; 49(3):409-422.
-
Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescence. Neuropsychopharmacology. 2026 Jun; 51(7):1310-1324.
-
From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care. Transl Behav Med. 2026 Jan 07; 16(1).
-
Reported Safety Practices of Publicly Advertised Psychedelic Retreats. JAMA Netw Open. 2026 01 02; 9(1):e2552505.
-
Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with obsessive-compulsive disorder: international findings from the LATINO Study. Braz J Psychiatry. 2026; 48:e20254316.
-
A landscape analysis of psychedelic retreat organizations advertising online. PLoS One. 2025; 20(5):e0321648.
-
Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use. J Psychoactive Drugs. 2026 Jul-Aug; 58(3):286-297.
-
Supportive Touch in Psychedelic Assisted Therapy. Am J Bioeth. 2025 01; 25(1):29-39.